Wednesday, August 13, 2025 8/13/2025

Moving TIL Therapy Past the Valley of Death

Award Number: U44CA165607
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/26/2011
PERIOD OF PERFORMANCE END DATE: 08/31/2015

Group Awards By:

View Award Description

Moving TIL Therapy Past the Valley of Death - DESCRIPTION (provided by applicant): The Field: The most effective treatment for metastatic melanoma is Tumor Infiltrating Lymphocyte (TIL) therapy, in which TILs are obtained from a patient's tumor fragments, grown to an immense quantity in vitro, and infused back into the patient (1-4). The Problem: Despite its ability to provide complete remission, the process of growing a therapeutic cell dose is so inefficient and complicated that TIL therapy cannot escape the Valley of Death. The Proposed Solution: Under prior Phase II SBIR GM058978, we created a paradigm shift in cell culture device technology that has been extensively studied for TIL production. The results demonstrate a greatly simplified process can be created that will allow TIL therapy to move beyond the Valley of Death and onto a commercial path. The key is to allow TILs to reside on a highly gas permeable, liquid impermeable membrane submerged under an unconventionally high level of medium. We call this approach "G-Rex". With TILs in this position, they have access to oxygen and nutrients on demand without need of expensive and complicated ancillary equipment. Using this device configuration, we intend to reduce the TIL production process from up to 60 conventional devices and 30L of medium to just 2 G-Rex devices and as little as 4L to 5L of medium. Many other production advantages are inherent to this level of process simplification. As a result of this program, the potential for profit by applying TIL therapy will exist and commercial entities will be spurred to capitalize on the powerful outcomes of TIL therapy. The Investigation: Our investigation will provide the most efficient TIL production possible by optimizing G- Rex Protocols and devices: Aim 1: Determine the optimal TIL surface density that minimizes the duration of TIL Rapid Expansion Process Aim 2: Determine the optimal height of the G-Rex that will minimize the feeding frequency during the TIL Rapid Expansion Process (REP). Aim 3: Define the variance of gas permeable membrane thickness allowed in full scale G-Rex devices. Aim 4: Full scale validation of optimized G-Rex TIL culture S.O.P.s and G-Rex device specifications. The status of TIL therapy upon completion of this program: Separate from this optimization program, clinical application of G-Rex in the non-optimized state is already occurring. Upon completion of this investigation, the optimized G-Rex will transition into a multi-center comparability study followed by a randomized study, FDA approval, and commercially available TIL therapy.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2014 ( Subtotal = $200,624 )
2014	2014	WILSON WOLF MANUFACTURING CORPORATION INC	33 5TH AVE NW, SUITE 700	NEW BRIGHTON	MN	55112	RAMSEY	USA	Cancer Treatment Research	000	6	9/12/2014	SUPPLEMENT FOR EXPANSION	$200,624
														Subtotal = $200,624

Issue Date FY: 2013 ( Subtotal = $611,581 )
2013	2013	WILSON WOLF MANUFACTURING CORPORATION INC	33 5TH AVE NW, SUITE 700	NEW BRIGHTON	MN	55112	RAMSEY	USA	Cancer Treatment Research	000	6	9/18/2013	NON-COMPETING CONTINUATION	$611,581
														Subtotal = $611,581

Issue Date FY: 2012 ( Subtotal = $15,918 )
2012	2012	WILSON WOLF MANUFACTURING CORPORATION INC	33 5TH AVE NW, SUITE 700	NEW BRIGHTON	MN	55112	RAMSEY	USA	Cancer Treatment Research	000	5	9/7/2012	NON-COMPETING CONTINUATION	$1
2012	2012	WILSON WOLF MANUFACTURING CORPORATION INC	33 5TH AVE NW, SUITE 700	NEW BRIGHTON	MN	55112	RAMSEY	USA	Cancer Treatment Research	001	5	9/26/2012	NON-COMPETING CONTINUATION	$15,917
														Subtotal = $15,918

Issue Date FY: 2011 ( Subtotal = $343,484 )
2011	2011	WILSON WOLF MANUFACTURING CORPORATION INC	33 5TH AVE NW, SUITE 700	NEW BRIGHTON	MN	55112	RAMSEY	USA	Cancer Treatment Research	000	4	9/26/2011	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$343,484
														Subtotal = $343,484

Grand Total All Awards = $1,171,607

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Moving TIL Therapy Past the Valley of Death

Award Number: U44CA165607

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/26/2011

PERIOD OF PERFORMANCE END DATE: 08/31/2015

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer